インデックス付き
  • Jゲートを開く
  • Genamics JournalSeek
  • アカデミックキー
  • ジャーナル目次
  • 中国国家知識基盤 (CNKI)
  • ウルリッヒの定期刊行物ディレクトリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • 雑誌の抄録索引作成ディレクトリ
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • Google スカラー
このページをシェアする
ジャーナルチラシ
Flyer image

概要

High Fluence Low Intensity Laser Irradiation Bioinhibits Viability and Proliferation of Lung Cancer Stem Cells

Anine Crous and Heidi Abrahamse

Small populations of pancreatic cancer cells from Patient Derived Xenografts (PDXs) were demonstrated to be highly tumorigenic and chemotherapy resistant. The cancer cells isolated from the xenograft tumor tissue were sorted by the previously reported "Cancer Stem Cell" (CSC) markers and tested their tumorigenic activity in the limiting dilution assay by inoculating into the immuno-deficient NOD/scid mice subcutaneously. The varied correlation between the CSC marker expression and the tumorigenic activity in the NOD/scid mice among the different PDXs indicates that the CSC markers of the individual pancreatic tumor patients could be different each other. Only a part of PDX tumor samples among the six examined could show a tight correlation between the tumor initiating activity and the selectively higher expression of cell surface markers CD24, CD44 and CD133. We also demonstrated that CD133/CD44 double positive population from the one PDX shows superior tumorigenic activity and gemcitabine treatment resistance. To illuminate the characteristically expressed genes which allow them to have tumorigenic activity and chemotherapy resistance, the CD133/CD44 double positive CSC faction was subjected to the gene expression analysis. Prominently higher expression of epiregulin (11.1-fold increase compared to the double negative population), interleukin-8 and CXCL5 (8.5- and 8.0-fold increases, respectively) were observed in the CSC fraction. These gene signatures of CSC suggest several key molecular mechanisms playing important roles in CSC biology and having possibilities as drug targets for CSC therapy.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません